-
Mashup Score: 2
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
Recently, a man aged 50 years came to my office. He had received surgery for a right-sided non-functional adrenocortical carcinoma measuring 11 cm in diameter and had been referred to discuss adjuvant treatment. Based on adrenal histology findings, he had a European Network for the Study of Adrenal Tumors (ENS@T) tumour stage II, which means no lymph node metastases, and a [18F]fluorodeoxyglucose-PET scan had ruled out distant metastasis.1 Fortunately, he had undergone oncological tumour resection resulting in complete resection.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Linked Comment by Martin Reincke: Good news for patients with #adrenocortical #carcinoma from the ADIUVO trial https://t.co/LDK290bhAr #adrenal #ACC #FREE to read with registration (also FREE)
-
-
Mashup Score: 4
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Online—Adjuvant #mitotane versus surveillance in low-grade, localised #adrenocortical #carcinoma (#ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study https://t.co/Ujp2h9u9hd #adrenal #ACC
-
-
Mashup Score: 1
Recently, a man aged 50 years came to my office. He had received surgery for a right-sided non-functional adrenocortical carcinoma measuring 11 cm in diameter and had been referred to discuss adjuvant treatment. Based on adrenal histology findings, he had a European Network for the Study of Adrenal Tumors (ENS@T) tumour stage II, which means no lymph node metastases, and a [18F]fluorodeoxyglucose-PET scan had ruled out distant metastasis.1 Fortunately, he had undergone oncological tumour resection resulting in complete resection.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Linked Comment by Martin Reincke: Good news for patients with #adrenocortical #carcinoma from the #ADIUVO trial https://t.co/LDK290bhAr #adenal #ACC
-
-
Mashup Score: 0
Recently, a man aged 50 years came to my office. He had received surgery for a right-sided non-functional adrenocortical carcinoma measuring 11 cm in diameter and had been referred to discuss adjuvant treatment. Based on adrenal histology findings, he had a European Network for the Study of Adrenal Tumors (ENS@T) tumour stage II, which means no lymph node metastases, and a [18F]fluorodeoxyglucose-PET scan had ruled out distant metastasis.1 Fortunately, he had undergone oncological tumour resection resulting in complete resection.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Martin Reincke comments: Good news for patients with #adrenocortical carcinoma from the #ADIUVO trial https://t.co/LDK290bhAr #adrenal #ACC
-
-
Mashup Score: 5
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
#Adjuvant #mitotane versus surveillance in low-grade, localised #adrenocortical #carcinoma (#ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study https://t.co/Ujp2h9u9hd #adrenal #ACC #OpenAccess https://t.co/lvnr6A5ESs
-
-
Mashup Score: 2
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Online—Adjuvant #mitotane versus surveillance in low-grade, localised #adrenocortical #carcinoma (#ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study https://t.co/Ujp2h9uH6L #adrenal #ACC #OpenAccess
-
-
Mashup Score: 1Cover Story | Pulmonary Hypertension and the Right Ventricle: Forgotten No More - American College of Cardiology - 9 month(s) ago
After decades of playing second fiddle to its more red-blooded, muscular, high-pressure partner on the left side of the heart, the weaker, low-pressure right ventricle (RV) is finding its independent identity both as a formidable prognosticator, with a strong impact on mortality in cardiovascular health, in heart failure (HF) across the ejection fraction spectrum, and as a major player in outcomes in valvular heart failure intervention. With a new definition of pulmonary hypertension (PH), fresh guidelines
Source: www.acc.orgCategories: Cardiologists, Latest HeadlinesTweet-
#ACC Cardiology Magazine Cover Story | Pulmonary Hypertension and the #RightVentricle: Forgotten No More https://t.co/J4aHGyqcyj @JACCJournals https://t.co/Sb9XhvaaKR
-
-
Mashup Score: 2
A long-cherished dream of mine came to fruition last November: I matched at the University of Minnesota for cardiology fellowship. My experiential journey that led to this fellowship match started with my MBBS training in India, followed by residency in a New York City program and was enriched by the contributions of incredible physicians. I first got drawn to cardiology during my stint as a…
Source: American College of CardiologyCategories: Cardiologists, Latest HeadlinesTweet-
One Woman, One Dream, Many Guiding Beacons - American College of Cardiology from @snehanandy26 on her experience in the #ACC Residence program and #ACCWIC #mentoring https://t.co/pmLd2EzP07
-
-
Mashup Score: 1ACC Announces New 2024 Officers, Trustees - 9 month(s) ago
July 20, 2023 — The ACC Board of Trustees (BOT) has approved the College’s newest officers and trustees who will assume their roles in April 2024 following ACC.24 in Atlanta, Ga. These new officers, put forth by the ACC Nominating Committee, include: Cathleen Dalton Biga, MSN, RN, FACC (ACC President) Christopher Kramer, MD, FACC (ACC Vice President) Bonnie Ky, MD, MSCE, FACC (Trustee) Lee R. Goldberg, MD, MPH, FACC (Trustee) These individuals will join Himabindu Vidula, MD, MS, FACC (BOG Chair/ACC Secretary), Akshay K. Khandelwal, MD, FACC (Finance Committee Chair), B. Hadley Wilson, MD, FACC, (Immediate-Past President), Jeffrey Kuvin, MD, FACC (Trustee), Sandra J. Lewis, MD, FACC (Trustee), Thomas M. Maddox, MD, MSc, FACC (Trustee), Roxana Mehran, MD, FACC (Trustee), Pamela B. Morris, MD, FACC (Trustee), and Hani Najm, MD, FACC (Trustee). “The next year will be pivotal for the College as we kick off our 2024-2028 Strategic Plan and celebrate 75 years of serving as the professi
Source: www.dicardiology.comCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @ACCinTouch The #ACC Board of Trustees (#BOT) has approved the College's newest officers and trustees who will assume their roles in April 2024 following #ACC24 in Atlanta: https://t.co/l1M2g2kUoW
-
In the October Issue: #Adjuvant #mitotane versus #surveillance in low-grade, localised #adrenocortical #carcinoma (#ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study https://t.co/Ujp2h9u9hd #adrenal #ACC #OpenAccess